Michael Bromley

Michael Bromley is a Lecturer in Drug Discovery at the Manchester Fungal Infection Group (MFIG) within the University of Manchester. He holds the title of Prof Chair in the Division of Evolution, Infection and Genomics. His research focuses on the mechanistic basis of fungal pathogenicity with a translational emphasis on developing novel antifungal agents. He led efforts at F2G Ltd, a University of Manchester spin-out, to identify drug targets in Aspergillus fumigatus and advance these to clinical trials. Bromley coordinates the €6.1M FP7 program NOFUN, driving antifungal drug development from discovery to trials.

Research Interests: Bromley’s work centers on fungal pathogenicity mechanisms, antifungal drug discovery, and genetic elements in A. fumigatus. His team developed methods like high-throughput gene replacement and chemical genetic screens to study fungal genetics and drug action. He investigates resistance mechanisms to agricultural fungicides and their impact on clinical antifungals like olorofim.

Grants & Projects: As Principal Investigator (PI), he leads the Manchester Fungal Infection Group (MFIG), a project studying A. fumigatus in infections like chronic pulmonary aspergillosis. His NOFUN initiative aims to translate novel compounds into clinical use. He founded Syngenics Limited, a biotech spin-out, and contributes to policy via editorial roles like Policy@Manchester.

Impact: His work addresses global health challenges tied to fungal infections, including antifungal resistance and diagnostics. Media coverage highlights his research on agricultural fungicides driving drug resistance and fungal threats in climate change. Bromley’s contributions align with UN Sustainable Development Goals like good health and environmental sustainability.